Bayer

China’s Center of Drug Evaluation accepts marketing authorization application for asundexian in stroke prevention after a non-cardioembolic ischemic stroke or transient ischemic attack

29 Apr 2026

New study highlights societal optimism toward breakthrough science, and rising anxiety about how fast the world is changing

29 Apr 2026

Bayer partners with U.N. International Organization for Migration (IOM) to fight hunger and strengthen food security in vulnerable communities

28 Apr 2026

“We see great progress, but the work isn’t complete yet”

24 Apr 2026

Annual Stockholders' Meeting 2026

24 Apr 2026

Bayer Foundation and the UN Capital Development Fund announce inaugural investments of the Food Systems Innovation Finance Facility in agri-businesses Omia and SokoFresh

22 Apr 2026

AskBio's Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD Investigational Gene Therapy Phase II Trial for Parkinson’s Disease

20 Apr 2026

Phase III study results with Bayer’s FXIa inhibitor demonstrating substantial reduction in ischemic stroke with no increase in ISTH major bleeding versus placebo published in New England Journal of Medicine

20 Apr 2026

Bayer’s strongest-ever pharma portfolio and promising pipeline drive future growth

02 Apr 2026

AskBio Announces Completion of Enrollment in Phase 2 Clinical Trial of AB-1002 Investigational Gene Therapy for Heart Failure

02 Apr 2026

View details about the software product Informachine News Trackers